KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to -$74.1 million.

  • Alnylam Pharmaceuticals' Other Non Operating Income fell 15111.76% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.1 million, marking a year-over-year decrease of 7572.59%. This contributed to the annual value of -$180.6 million for FY2024, which is 4371.51% down from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Other Non Operating Income is -$74.1 million, which was down 15111.76% from -$6.4 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Other Non Operating Income high stood at $19.0 million for Q1 2021, and its period low was -$80.8 million during Q4 2024.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Non Operating Income had a median value of -$30.5 million in 2021 and averaged -$32.2 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Non Operating Income surged by 308232.32% in 2021 and then plummeted by 69155.97% in 2023.
  • Alnylam Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$30.5 million in 2021, then skyrocketed by 91.57% to -$2.6 million in 2022, then tumbled by 691.56% to -$20.4 million in 2023, then plummeted by 297.26% to -$80.8 million in 2024, then increased by 8.28% to -$74.1 million in 2025.
  • Its Other Non Operating Income stands at -$74.1 million for Q3 2025, versus -$6.4 million for Q2 2025 and -$49.7 million for Q1 2025.